{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:26:03Z","timestamp":1761895563492},"reference-count":15,"publisher":"Hindawi Limited","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"name":"Fundaci\u00f3n para el estudio de la Hematologia y Hemoterapia en Arag\u00f3n"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Oncology"],"published-print":{"date-parts":[[2012]]},"abstract":"<jats:p><jats:italic>Background<\/jats:italic>. Based on historical data we reviewed our hospital clinical database to analyse our updated information and therapy outcomes of follicular non-Hodgkin lymphoma (F-NHL) patients treated with<jats:sup>90<\/jats:sup>Y-Ibritumomab tiuxetan.<jats:italic>Patients and Methods<\/jats:italic>. Between 2005 and 2011, 56 F-NHL patients were included in a clinical protocol conducted by a multidisciplinary team and treated in the same centre. All patients received 0.3 or 0.4\u2009mCi\/kg IV (88%) of<jats:sup>90<\/jats:sup>Y-IT; response evaluation was performed 12 weeks after.<jats:italic>Results<\/jats:italic>. M\/F 44.6%\/55.4%, mean age 61.45 years (30\u201385); ECOG 0-1 96.9%. According to FLIPI score, distribution were good: 58.5%, intermediate: 29.2%, and poor: 12.3%. Previous therapies: &gt;2: 40% (26). ORR was 94.6% (53\/56). CR: 85.7%; CR according to previous disease: relapsed disease: 90% (27\/30), refractory disease: 42.85% (3\/7), consolidation with CR: 92.85% (13\/14), and consolidation with PR: 100% (5\/5). Global PR and NR were 8.9% (5) and 5.3% (3), respectively. Mean OS 63.86 months with a mean follow-up time of 57 months (2\u201373). Mean TTP: 52.65 months (95% CI: 43.83\u201361.48). Median OS and TTP were not achieved. No hospital submissions or deaths were registered.<jats:italic>Conclusions<\/jats:italic>. This study confirms the safety and high efficacy of<jats:sup>90<\/jats:sup>Y-IT in F-NHL patients, RIT in early stage of disease could improve outcomes.<\/jats:p>","DOI":"10.1155\/2012\/412742","type":"journal-article","created":{"date-parts":[[2012,9,26]],"date-time":"2012-09-26T07:42:26Z","timestamp":1348645346000},"page":"1-5","source":"Crossref","is-referenced-by-count":5,"title":["RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution"],"prefix":"10.1155","volume":"2012","author":[{"given":"Marcio Miguel","family":"Andrade Campos","sequence":"first","affiliation":[{"name":"Department of Haematology, Miguel Servet University Hospital, Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anel E.","family":"Montes Lim\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Haematology, Miguel Servet University Hospital, Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Mar\u00eda","family":"Grasa","sequence":"additional","affiliation":[{"name":"Department of Haematology, Miguel Servet University Hospital, Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Lievano","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Miguel Servet University Hospital, Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Baringo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Miguel Servet University Hospital, Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[{"name":"Department of Haematology, Miguel Servet University Hospital, Zaragoza, Spain"},{"name":"Instituto Aragon\u00e9s de Ciencias de la Salud (I+CS), Zaragoza, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER). Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"issue":"5","key":"2","first-page":"58","volume":"26","year":"1999","journal-title":"Seminars in Oncology"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.03.005"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.2009-S2-17","volume":"14","year":"2009","journal-title":"The Oncologist"},{"key":"7","first-page":"131","volume":"2","year":"2009","journal-title":"Cancer Management and Research"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.044"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3883"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.054"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.8748"},{"issue":"12","key":"12","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","volume":"17","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22617"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22066"}],"container-title":["Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2012\/412742.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2012\/412742.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jo\/2012\/412742.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T00:40:04Z","timestamp":1498005604000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.hindawi.com\/journals\/jo\/2012\/412742\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":15,"alternative-id":["412742","412742"],"URL":"https:\/\/doi.org\/10.1155\/2012\/412742","relation":{},"ISSN":["1687-8450","1687-8469"],"issn-type":[{"value":"1687-8450","type":"print"},{"value":"1687-8469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}